The long-term objectives of this project are to understand the workings of glucocorticoids and the glucocorticoid receptor in human leukemic cells. In the last four years and two months, we have accomplished most of the major aims originally proposed; we expect to complete the significant ones remaining in the next ten months. In addition, we have obtained new results extending beyond the original aims. To date we have, as originally proposed, successfully collaborated in the cloning and sequencing of the human glucocorticoid receptor (hGR) cDNA; obtained and used both mono- and polyclonal antibodies to the hGR; discovered an RFLP in a family with Primary Cortisol Resistance; further defined the nature of the receptor defects in clones of glucocorticoid-resistant human leukemia CEM cells; shown that cortivazol's two binding sites in CEM C7 cells are both on hGR; shown that hGR+/lysis- CEM cells complement hGR- mutants; found that of the oncogenes tested, only c-myc is acutely, profoundly down-regulated by glucocorticoid, showing that this process requires both the GR and """"""""lysis function."""""""" In extensions of the original aims, we have also: overexpressed hGR in the baculovirus system and found that this hGR is extremely potent in stimulating glucocorticoid response element-driven, cell free transcription; shown that hGR is induced by dexamethasone in a line of myeloma cells; begun to map hGR for its ability to kill transfected leukemic cells, with and without ligand; and sequenced about 5000 bp of the 5' flank of the hGR, identifying a previously undescribed first exon and several transcription start sites. Based on our results, we propose to carry out new experiments designed to explain glucocorticoid receptor action at the gene level, to define the topology of the receptor responsible for cell kill, to test the hypothesis that the c-myc gene is a critical site of action for glucocorticoids as they evoke a lethal response in leukemic cells, and to study the regulation of the receptor itself. We will characterize further the overexpressed hGr and use the purified protein to study GR biochemistry. In cell-free systems we want to study both up- and down-regulation of certain genes transcribed by RNA polymerase I or II under the control of glucocorticoid receptors, using our overexpressed hGR to drive the in vitro reactions. We will determine the level(s) at which myc is regulated by glucocorticoids in CEM cells. We will test in several ways the hypothesis that c-myc is a critical regulated step in the lethal response of CEM cells to glucocorticoids. We will map in detail the hGR for the regions necessary for cell kill, seeking the fragment that can efficiently bring about leukemic cell death in the absence of steroid. Finally, we will determine the region of the hGR promoter/enhancer responsible for the inducibility of the hGR itself in CEM cells and will find what transcription factors bind and interact to bring about that response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041407-08
Application #
3181858
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1985-12-01
Project End
1995-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Webb, M S; Miller, A L; Howard, T L et al. (2018) Sequential gene regulatory events leading to glucocorticoid-evoked apoptosis of CEM human leukemic cells:interactions of MAPK, MYC and glucocorticoid pathways. Mol Cell Endocrinol 471:118-130
Aiyar, Sarah E; Park, Hoyong; Aldo, Paulomi B et al. (2010) TMS, a chemically modified herbal derivative of resveratrol, induces cell death by targeting Bax. Breast Cancer Res Treat 124:265-77
Garza, Anna S; Miller, Aaron L; Johnson, Betty H et al. (2009) Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions. Leuk Res 33:717-27
Ji, Zhenyu; Mei, Fang C; Miller, Aaron L et al. (2008) Protein kinase A (PKA) isoform RIIbeta mediates the synergistic killing effect of cAMP and glucocorticoid in acute lymphoblastic leukemia cells. J Biol Chem 283:21920-5
Ji, Zhenyu; Mei, Fang C; Johnson, Betty H et al. (2007) Protein kinase A, not Epac, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J Biol Chem 282:37370-7
Webb, M S; Miller, A L; Thompson, E Brad (2007) In CEM cells the autosomal deafness gene dfna5 is regulated by glucocorticoids and forskolin. J Steroid Biochem Mol Biol 107:15-21
Miller, Aaron L; Webb, M Scott; Thompson, E Brad (2007) Comparison of two structurally diverse glucocorticoid receptor agonists: cortivazol selectively regulates a distinct set of genes separate from dexamethasone in CEM cells. Steroids 72:673-81
Ilies, Marc Antoniu; Seitz, William A; Johnson, Betty H et al. (2006) Lipophilic pyrylium salts in the synthesis of efficient pyridinium-based cationic lipids, gemini surfactants, and lipophilic oligomers for gene delivery. J Med Chem 49:3872-87
Copik, Alicja J; Webb, M Scott; Miller, Aaron L et al. (2006) Activation function 1 of glucocorticoid receptor binds TATA-binding protein in vitro and in vivo. Mol Endocrinol 20:1218-30
Miller, Aaron L; Webb, M Scott; Copik, Alicja J et al. (2005) p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19:1569-83

Showing the most recent 10 out of 46 publications